Corporate News

Director/PDMR Shareholding

19 April 2021

Omega Diagnostics (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces that Derek Brady, Group Strategic Sourcing Director has sold in total 14,673 ordinary shares of 4 pence each in the capital of the Company (“Ordinary Shares”), at a price of 95 pence per share. Following the sale Mr. Brady holds no Ordinary Shares.

 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.

 

Contacts:  

Omega Diagnostics Group PLCTel: 01259 763 030
Bill Rhodes, Interim Non-Executive Chairman  
Colin King, Chief Executive		www.omegadiagnostics.com
Kieron Harbinson, Group Finance Director  
  
finnCap LtdTel: 020 7220 0500
Geoff Nash/Edward Whiley (Corporate Finance)  
Alice Lane (ECM)  
  
Walbrook PR Limited Tel: 020 7933 8780 or [email protected]
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1  Details of the person discharging managerial responsibilities/person closely associated
a. Name Derek Brady
2  Reason for notification
a. Position/Status PDMR (Group Strategic Sourcing Director)
b. Initial notification/
Amendment 		Initial Notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a. Name Omega Diagnostics Group Plc
b. LEI 2138007U9P4BTZTYIR92
4  Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a. Description of the financial instrument,
type of instrument
 
Identification Code 		 Ordinary Shares of 4 pence each
  
ISIN: GB00B1VCP282
b. Nature of the transaction Acquisition of Ordinary Shares following the Exercise of Share Options and Sale of Ordinary Shares
c. Price(s) and volume(s)  
    
 
   		Price(s) Volume(s)   
Purchase
Sale
    
 
   		95p 14,673 
d. Aggregated information
Aggregated Purchase
Volume
Aggregated Purchase Price
Aggregated Sale Volume
Aggregated Sale Price 		As above.      
e. Date of the transaction 13 April 2021   
f. Place of the transaction London Stock Exchange   

Sign up for Investor Alerts